H. pylori Diagnostic Approach and Treatment Strategy

Diagnostic Performance and Test Selection

The American Gastroenterological Association recommends using a validated laboratory-based monoclonal antibody stool antigen test for both initial diagnosis and post-treatment confirmation of H. pylori infection, with equivalent accuracy to the urea breath test and 93% sensitivity and specificity 1, 2
The European Helicobacter Study Group suggests that laboratory-based monoclonal SAT is the recommended format with ELISA methodology, achieving high accuracy for both initial diagnosis and post-treatment testing 1, 2

For patients under 50-55 years without alarm symptoms, the American College of Gastroenterology recommends using the "test and treat" strategy with non-invasive testing, which reduces unnecessary endoscopies by 62% while maintaining equivalent safety and symptom resolution 6, 4
The European Society of Gastrointestinal Endoscopy advises proceeding directly to endoscopy with invasive testing for patients over 50 years or with alarm symptoms, such as bleeding, weight loss, dysphagia, anemia, or palpable mass 4

The American Gastroenterological Association recommends performing test-of-cure at least 4 weeks after completing eradication therapy using laboratory-based monoclonal SAT or UBT, with sensitivity and specificity of 91.6% and 98.4%, respectively 1, 2, 5
The Infectious Diseases Society of America suggests never using serology for post-treatment confirmation as antibodies remain elevated after eradication 4

The American College of Gastroenterology recommends first-line treatment with 14-day bismuth quadruple therapy or 14-day concomitant therapy for treatment-naive patients with confirmed H. pylori 5

The European Helicobacter Study Group states that stool antigen testing is safe in children and pregnant women, unlike radioactive 13C-UBT 3
The Centers for Disease Control and Prevention recommends testing first-generation immigrants from high-prevalence countries, family members of patients with gastric cancer or peptic ulcer disease, and patients with unexplained iron-deficiency anemia, idiopathic thrombocytopenic purpura, or vitamin B12 deficiency 4, 1, 2